• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Antigenic sites of coxsackie A9 virus inducing neutralizing monoclonal antibodies protective in mice.

作者信息

Buttinelli Gabriele, Donati Valentina, Ruggeri Franco M, Joki-Korpela Paivi, Hyypia Timo, Fiore Lucia

机构信息

Laboratory of Virology, Istituto Superiore di Sanità, Rome 299-00161, Italy.

出版信息

Virology. 2003 Jul 20;312(1):74-83. doi: 10.1016/s0042-6822(03)00182-x.

DOI:10.1016/s0042-6822(03)00182-x
PMID:12890622
Abstract

A panel of murine IgG monoclonal antibodies (MAbs) was produced against coxsackievirus A9 (CAV9). Fifty-nine MAbs reactive in ELISA with purified CAV9 were identified. Eighteen of them could efficiently inhibit infection by CAV9 but not coxsackieviruses B. Neutralization-resistant CAV9 variants to four different MAbs were isolated and tested for resistance to neutralization by other MAbs of the panel. Three groups of reactivity including 10, 7, and 1 MAbs were thus identified. Sequencing of neutralization-escape virus mutants showed that neutralization by one MAb group was affected by change of VP3 amino acids 62 or 69. For the second group of reactivity, mutations included amino acids 154 or 165 of VP2. The only MAb of the third group selected for a change at residue 70 of VP2. Protection studies in a newborn mouse model of myositis suggested that either epitopes in VP2 or in VP3 mediate protection from CAV9 infection in vivo.

摘要

相似文献

1
Antigenic sites of coxsackie A9 virus inducing neutralizing monoclonal antibodies protective in mice.
Virology. 2003 Jul 20;312(1):74-83. doi: 10.1016/s0042-6822(03)00182-x.
2
Poliovirus Sabin type 1 neutralization epitopes recognized by immunoglobulin A monoclonal antibodies.脊髓灰质炎病毒1型萨宾株被免疫球蛋白A单克隆抗体识别的中和表位
J Virol. 1997 Sep;71(9):6905-12. doi: 10.1128/JVI.71.9.6905-6912.1997.
3
Characterization of neutralization sites on the circulating variant of swine vesicular disease virus (SVDV): a new site is shared by SVDV and the related coxsackie B5 virus.猪水疱病病毒(SVDV)循环变体中和位点的特征:SVDV与相关柯萨奇B5病毒共享一个新位点。
J Gen Virol. 2002 Jan;83(Pt 1):35-44. doi: 10.1099/0022-1317-83-1-35.
4
Identification of group I porcine enteroviruses by monoclonal antibodies in cell culture.利用单克隆抗体在细胞培养中鉴定I型猪肠道病毒
Vet Microbiol. 1999 Jun 1;67(1):1-12. doi: 10.1016/s0378-1135(99)00024-3.
5
Identification of the location of antigenic sites of swine vesicular disease virus with neutralization-resistant mutants.用中和抗性突变体鉴定猪水疱病病毒抗原位点的位置
J Gen Virol. 1995 Dec;76 ( Pt 12):3099-106. doi: 10.1099/0022-1317-76-12-3099.
6
Conformation of the VP2 protein of bluetongue virus (BTV) determines the involvement in virus neutralization of highly conserved epitopes within the BTV serogroup.蓝舌病病毒(BTV)VP2蛋白的构象决定了BTV血清群内高度保守表位参与病毒中和反应的情况。
J Gen Virol. 1990 Jun;71 ( Pt 6):1325-32. doi: 10.1099/0022-1317-71-6-1325.
7
Identification of neutralizing epitopes on a European strain of swine vesicular disease virus.欧洲猪水泡病病毒株中和表位的鉴定
J Gen Virol. 1999 Feb;80 ( Pt 2):277-282. doi: 10.1099/0022-1317-80-2-277.
8
[The isolation and characteristics of monoclonal antibodies to the structural proteins of Coxsackie B5 virus].
Vopr Virusol. 1994 Mar-Apr;39(2):80-2.
9
Characterization of monoclonal antibodies against a type SAT 2 foot-and-mouth disease virus.针对SAT 2型口蹄疫病毒的单克隆抗体的特性分析
Epidemiol Infect. 1993 Oct;111(2):391-406. doi: 10.1017/s0950268800057083.
10
Monoclonal antibodies, against O1 serotype foot-and-mouth disease virus, from a natural bovine host, recognize similar antigenic features to those defined by the mouse.来自天然牛宿主的抗O1血清型口蹄疫病毒单克隆抗体识别与小鼠所定义的相似抗原特征。
J Gen Virol. 1998 Jul;79 ( Pt 7):1687-97. doi: 10.1099/0022-1317-79-7-1687.

引用本文的文献

1
Discovery of a broad-spectrum monoclonal antibody recognizing a conserved, linear epitope WFYDGYPT on VP1 protein of Enterovirus A species.发现一种广谱单克隆抗体,该抗体识别肠道病毒A种VP1蛋白上一个保守的线性表位WFYDGYPT。
Virol J. 2024 Dec 30;21(1):338. doi: 10.1186/s12985-024-02596-4.
2
Integrins are not essential for entry of coxsackievirus A9 into SW480 human colon adenocarcinoma cells.整合素对于柯萨奇病毒A9进入SW480人结肠腺癌细胞并非必不可少。
Virol J. 2016 Oct 18;13(1):171. doi: 10.1186/s12985-016-0619-y.
3
Precise genotyping and recombination detection of Enterovirus.
肠道病毒的精确基因分型与重组检测
BMC Genomics. 2015;16 Suppl 12(Suppl 12):S8. doi: 10.1186/1471-2164-16-S12-S8. Epub 2015 Dec 9.
4
Protection against lethal enterovirus 71 challenge in mice by a recombinant vaccine candidate containing a broadly cross-neutralizing epitope within the VP2 EF loop.一种含有广泛中和表位的重组疫苗候选物对小鼠致死性肠道病毒 71 挑战的保护作用,该表位位于 VP2 EF 环内。
Theranostics. 2014 Feb 18;4(5):498-513. doi: 10.7150/thno.7457. eCollection 2014.
5
Coxsackievirus A9 infects cells via nonacidic multivesicular bodies.柯萨奇病毒 A9 通过非酸性多泡体感染细胞。
J Virol. 2014 May;88(9):5138-51. doi: 10.1128/JVI.03275-13. Epub 2014 Feb 26.
6
Development of a sensitive and specific epitope-blocking ELISA for universal detection of antibodies to human enterovirus 71 strains.建立一种敏感和特异的表位阻断 ELISA 法,用于通用检测人肠道病毒 71 型抗体。
PLoS One. 2013;8(1):e55517. doi: 10.1371/journal.pone.0055517. Epub 2013 Jan 31.
7
Characterization and specificity of the linear epitope of the enterovirus 71 VP2 protein.肠道病毒 71 型 VP2 蛋白线性表位的鉴定及特异性分析。
Virol J. 2012 Feb 24;9:55. doi: 10.1186/1743-422X-9-55.
8
Widespread circulation of echovirus type 13 demonstrated by increased seroprevalence in Toyama, Japan, between 2000 and 2003.2000年至2003年期间,日本富山县血清阳性率上升表明肠道病毒13型广泛传播。
Clin Vaccine Immunol. 2010 May;17(5):764-70. doi: 10.1128/CVI.00239-09. Epub 2010 Mar 24.
9
Internalization of coxsackievirus A9 is mediated by {beta}2-microglobulin, dynamin, and Arf6 but not by caveolin-1 or clathrin.柯萨奇病毒 A9 的内化是由β2-微球蛋白、动力蛋白和 Arf6 介导的,但不是由窖蛋白-1 或网格蛋白介导的。
J Virol. 2010 Apr;84(7):3666-81. doi: 10.1128/JVI.01340-09. Epub 2010 Jan 20.